Clinical Trial · NCT07689656

A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer

Overview

Primary Objective: To evaluate the safety and tolerability of PET imaging following a single intravenous infusion of \[⁶⁸Ga\]Ga-ELI421 injection in patients with prostate cancer. Secondary Objectives: To evaluate the biodistribution characteristics of \[⁶⁸Ga\]Ga-ELI421 injection; To evaluate the radiation dosimetry characteristics of \[⁶⁸Ga\]Ga-ELI421 injection; To evaluate the diagnostic efficacy of PET imaging with \[⁶⁸Ga\]Ga-ELI421 injection.

Sponsor

Norwegian University of Science and Technology

Phase

Phase 1/2

Contacts

Xiaoli Lan (CONTACT)

hzslxl@163.com

+86-2783692633

ClinicalTrials.gov

NCT07689656

Drug / Compound

ELI421

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Eligibility

Inclusion

Patients with histopathologically and/or cytologically confirmed prostate cancer;

Exclusion

Exclusion criteria not yet provided.